AzurRx BioPharma

85 articles with AzurRx BioPharma

• AzurRx BioPharma Announces Closing of $5.75 Million Bought Deal Offering and Exercise in Full of Underwriter’s Option to Purchase Additional Shares

  7/27/2021

  AzurRx BioPharma, Inc. announced the closing of its previously announced underwritten public offering of 10,454,546 shares of common stock of the Company, including the exercise in full by the underwriter of the option to purchase an additional 1,363,636 shares of common stock, at a price to the public of $0.55 per share.

• AzurRx BioPharma Increases Previously Announced Bought Deal to $5.0 Million

  7/23/2021

  AzurRx BioPharma, Inc. announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 9,090,910 shares of common stock of the Company, at a price to the public of $0.55 per share, less underwriting discounts and commissions.

• AzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common Stock

  7/22/2021

  AzurRx BioPharma, Inc. announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 5,454,546 shares of common stock of the Company, at a price to the public of $0.55 per share, less underwriting discounts and commissions.

• 

  Clinical Catch-Up: June 7-11

  6/14/2021

  A busy week for clinical trial news as the ASCO meeting wrapped up and the European Hematology Association 2021 Virtual Congress began. Read on for more.

• AzurRx BioPharma CEO James Sapirstein to Present at 2021 BIO Digital

  6/8/2021

  AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced that James Sapirstein, Chief Executive Officer of AzurRx, will present at the 2021 BIO Digital.

• AzurRx BioPharma Doses First Patient In Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

  6/7/2021

  AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced the administration of the first dose of FW-1022 to a volunteer in the ongoing Phase 2 RESERVOIR clinical trial.

• AzurRx BioPharma to Present at Rocky Mountain Microcap Conference (May 26)

  5/19/2021

  AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, AzurRx President, CEO and Chairman, will present at the Rocky Mountain Microcap Conference on May 26, 2021.

• AzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

  5/13/2021

  Data from first 18 patients indicate MS1819 and PERT combination led to clinically meaningful improvements in primary efficacy endpoint

• AzurRx BioPharma Receives Approximately $550K for its 2020 CIR (French Research Tax Credit)

  5/12/2021

  AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that AzurRx SAS, its wholly-owned subsidiary in France, has received approximately 459,000 Euros ($550,000 U.S.) in non-dilutive funding in research tax credits from the French government for its 2020 CIR

• AzurRx BioPharma to Present at the Emerging Growth Conference (May 12)

  5/11/2021

  AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the Company will make a virtual presentation at the Emerging Growth Conference taking place on Wednesday, May 12th, 2021.

• AzurRx BioPharma to Present at Investor Summit Group’s Q2 Virtual Investor Summit (May 17)

  5/11/2021

  AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, AzurRx President, CEO and Chairman, will present at Investor Summit Group’s Q2 Virtual Investor Summit taking place May 17-18, 2021.

• AzurRx BioPharma CEO Issues Letter to Shareholders - Apr 15, 2021

  4/15/2021

  AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, issued a letter to its shareholders from James Sapirstein, President, Chief Executive Officer and Chairman, highlighting the company’s corporate and clinical achievements during the first quarter of 2021 and recent weeks.

• AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated ColitisPhase 1b/2a Study Expected to Begin In 2Q 2021

  4/13/2021

  AzurRx BioPharma, Inc. (NASDAQ: AZRX ), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has entered into an agreement with PPD, Inc. (NASDAQ: PPD ), a leading global contract research organization (CRO), for its planned Phase 1b/2a clinical trial

• 

  Clinical Catch-Up: April 5-9

  4/12/2021

  It was a relatively quiet week for clinical trial announcements, but there were a few standouts. Read on for more.

• AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

  4/6/2021

  AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced that it has initiated its Phase 2 RESERVOIR clinical trial of a proprietary oral formulation of micronized niclosamide for the treatment of COVID-19 related gastrointestinal infections.

• AzurRx BioPharma to Report Topline Data from Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

  3/31/2021

  AzurRx BioPharma, Inc. announced that the Company will host a conference call and live audio webcast today, Wednesday, March 31, 2021, at 4:30 p.m. ET, to discuss the topline results from its Phase 2b OPTION 2 clinical trial investigating MS1819 in cystic fibrosis patients with exocrine pancreatic insufficiency.

• AzurRx BioPharma Provides Key Takeaways from Phase 2b OPTION 2 Clinical Trial Topline Results Conference Call

  3/31/2021

  AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today provided key takeaways from its conference call reporting on the topline results from its Phase 2b OPTION 2 clinical trial investigating MS1819 in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI)

• AzurRx BioPharma Announces Completion of Enrollment in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic InsufficiencyTop-line data expected in Q2 2021

  3/22/2021

  AzurRx BioPharma, Inc. announced it has completed enrollment in its Phase 2 trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy, for the treatment of severe exocrine pancreatic insufficiency in patients with cystic fibrosis.

• AzurRx BioPharma Announces Completion of Enrollment in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

  3/16/2021

  AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced it has completed enrollment for its Phase 2b OPTION 2 clinical trial to investigate MS1819 in cystic fibrosis patients with exocrine pancreatic insufficiency.

• AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18)

  3/10/2021

  AzurRx BioPharma, Inc.  (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, announced today that James